Format

Send to:

Choose Destination
See comment in PubMed Commons below
Anticancer Res. 2012 Nov;32(11):4723-8.

Initial activation status of the antioxidant response determines sensitivity to carboplatin/paclitaxel treatment of ovarian cancer.

Author information

  • 1Multidisciplinar Group of Translational Oncology, University Research Institute on Health Sciences, University of the Balearic Islands, Palma de Mallorca, Balearic Islands, Spain.

Abstract

BACKGROUND/AIM:

Ovarian carcinoma is the main cause of gynecological cancer related deaths. The aim of this study was to determine the activation status of the antioxidant response in samples of ovarian serous carcinoma from paraffin-embedded biopsies and compare them with the response of patients to carboplatin-paclitaxel treatment.

MATERIALS AND METHODS:

Estrogen receptor alpha (ERα), antioxidant enzymes, and uncoupling protein (UCP) levels were analyzed by western blotting and the presence of estrogen receptor beta (ERβ) was investigated by immunohistochemistry (IHC).

RESULTS:

Lower levels of ERα, antioxidant enzymes and UCPs were found in patients resistant to treatment in comparison to the carboplatin/paclitaxel-sensitive ones; IHC revealed a greater presence of ERβ in sensitive patients.

CONCLUSION:

These results indicate that patients resistant to treatment have a lower level of antioxidant response activation compared to sensitive patients, fact which may be related to the efficacy of this treatment.

PMID:
23155235
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk